You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Repligen Technical Seminar

Bioprocessing breakthroughs

and solutions that work

tuesday, 22 October 2019  |   London, UK

Repligen technical seminars are unique opportunities to discuss the changing landscape of bioprocessing with key thought leaders and experts around the world. Industry case studies in process intensification, continuous processing and flexible facilities allow you to learn from adopters of transformative technologies, evaluate risk landscapes and set the standards for modern bioproduction.

In 2019, major technology breakthroughs will be introduced that signal market shifts in bioprocessing.

Locations include Shanghai, Washington, D.C., San Francisco, London and Geneva.

Click here to view past seminar agendas.

The Natural History Museum |  Flett Events Theatre

Cromwell Road

London SW7 5BD United Kingdom


Expand All


Successful implementation of completely closed, single use system can result in substantial cost savings while also creating significant challenges. A case study describing the successful development and scaleup of a number of AAV processes -and a few pitfalls encountered along the way- will be presented.


In response to customers challenged with bioburden-sensitive TFF processes, technology leading single-use TangenX™ TFF flat sheet cassettes are now available in closed and irradiated format. Used in ultrafiltration and diafiltration, the new cassettes come pre-assembled and pre-tested, using the same proprietary membrane choices and multiple MWCOs as SIUS™ flat sheet cassettes. This session will demonstrate how the new cassettes integrate easily into any process with faster turnaround time, improved productivity and lower risk of contamination.

Speaker Bio

mike-labreck.jpgMichael LaBreck is Bioprocessing Sales Specialist for TangenX™ TFF products at Repligen starting in December 2016.  Before that, he supported the TangenX™ product line at NovaSep 2008- 2016. He has over 20 years experience with tangential flow filtration applications support in the biopharmaceutical industry.  He has held various sales and applications engineering positions with Pall Corporation and GE Healthcare. Michael has a Bachelor of Science degree in Mechanical Engineering from Syracuse University. 


Gene therapy has shown transformative potential towards a number of previously untreatable clinical conditions, using highly innovative approaches including autologous personalised therapies. Manufacturing challenges and limited production capabilities, however, result in a high cost of goods for clinical and commercial materials, which in turn, create real clinical, affordability and patient access issues. The need for genuinely innovative manufacturing process to address these challenges will be discussed.

Speaker Bio

Tony-Hitchcock.PNGTony has over 30 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programmes for the development of novel therapeutic products including protein, recombinant virus, bacteriophage and plasmid DNA products. His current role is based in the commercial group and support external collaboration and outreach activities.

Additionally, Tony is currently a member of the steering committee of BioProNET, the BIA Science and Innovation Advisory Committee (SIAC), and a serves on EPSRC, BBSRC and Vinnova review panels. He was also named in the Medicine Makers 2019 Power list as one of the industries’ top influencers. He has also served as a member of the BBSRC BSI (Biosciences for industry panel), the steering committee of the UK Bioprocess Research Industry Club (BRIC), the scientific advisory of the Pharmaceutical Centre for Excellence (COEBP) at the University of Manchester, the Executive Board of the European Federation of Biotechnology and the industrial advisory board for the Astbury Centre at the University of Leeds.


An innovative ligand, NGL-Impact® A, developed by Repligen with Navigo through rigorous gene shuffling, screening and multimerization, is the basis of a new capture resin that rivals current industry standards. Partners in innovation, Repligen and Purolite used a proprietary jetting-based bead manufacturing process to develop the novel Protein A resin, Praesto® Jetted A50, that has been shown to deliver high capacity, caustic stability and bead uniformity. Potential economic benefits include decreased initial resin cost, extended resin lifetime, lower buffer usage and less operation time.

Speaker Bio

Purolite(HR)-0640-Chris.pngChris has 17 years biotechnology experience, having spent time with GE Healthcare, WAVE Bioreactors and Merck Millipore, advising clients on start-to-finish protein purification and MAb bioprocessing. At Purolite he leads the global commercial operations of the agarose division.


As a bioprocessing innovator with technology expertise in filtration, Repligen has developed a breakthrough clarification and harvest technology that can signal a paradigm shift in mAbs and Gene Therapy bioprocessing. A result of continuous innovation at Repligen, the solution integrates advances in multiple disciplines, combining novel polymer technology, various filtration modes, hardware, systems and automated process management. Potential benefits to productivity, product quality, yield and workflow efficiency will be discussed.

Speaker Bio

Parra, Shelly.jpgShelly Parra has over 20 years of experience in biotherapeutic process development, scale-up, technology transfer, manufacturing, and validation. She is currently the head of the global Field Applications team at Repligen and works with customers optimizing and scaling both upstream and downstream unit operations.  Prior to Repligen, Parra was employed at Thermo Fisher Scientific, Amgen, Transkaryotic Therapies, and BASF Bioresearch. She holds BS and MS degrees in Biotechnology from Worcester Polytechnic Institute in Massachusetts.



There is no charge for attendance but registration is required. Seats are limited to end-users of bioprocessing tools and technologies. Travel, accomodations, and incidental expenses are the responsibility of attendees. Lunch will be served.